Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 100

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 100
---
, Series H Warrants, Series J Warrants, and
Series K Warrants, issued in prior transactions, pursuant to which the such holders agreed to exercise certain of such warrants in exchange
for a reduction in exercise price of each warrant to $3.10 per share. An aggregate of 20,041 warrants were exercised for aggregate gross
proceeds of approximately $62,000, before estimate offering expenses. We did not issue new warrants to replace the warrants that were
exercised.

| Item 8. | Exhibits and Financial Statement Schedules |

| (a) | The Exhibit Index is incorporated herein by reference. |

See the Exhibit
Index attached to this registration statement, which is incorporated herein by reference.

| (b) | Financial Statement Schedules. |

Schedules not
listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial
statements or the notes thereto.

| Item 9. | Undertakings |

The undersigned Registrant hereby undertakes:

| (1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this 
 registration statement:                                                                                |

| (i) | to include any prospectus required by section 10(a)(3) of the Securities Act; |

| (ii) | to reflect in the prospectus any facts or events arising after the effective date of the registration                                       
 statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change     
 in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities 
 offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or      
 high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule      
 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price    
 set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as amended, in                              
 the effective registration statement; and                                                                                                   |

| (iii) | to include any material information with respect to the plan of distribution not previously disclosed   
 in the registration statement or any material change to such information in the registration statement; |

Provided, however, that:

| (A